Off the wire
• Chinese airborne troops head for Belarus for drill  • Thailand's Bangkok Bank re-enters Cambodian market after 15-year absence  • Gunmen kill another former militant in Indian-controlled Kashmir  • Curry's 37 lift Warriors 3-2 lead over Cavs in finals  • New Zealand needs to deliver against China, says coach  • New Zealand military chief to seek greater cooperation with PLA  • Police seize property in probe into deadly Christchurch quake building  • 1st LD Writethru: CPC expels two former senior officials  • Napoleon Bonaparte's getaway ship found in Australian waters  • 1st LD: China stocks open higher Monday  
You are here: 　 Home

Australian research institute to produce trial cancer therapies

Xinhua, June 15, 2015 Adjust font size:

The Queensland Institute of Medical Research (QIMR) has been granted permission to manufacture and trial new cancer treatments aimed at rejuvenating patient immune systems, the Australian Broadcasting Corporation (ABC) reported on Monday.

The first Australian facility licensed to produce clinical grade T-cell therapies, the new cancer treatments will take a patient's immune cells from the blood and train them to recognize antigens found in particular cancers.

Once trained, the cells are re-infused back into the patient to attack the cancer. QIMR tumor immunologist Professor Rajiv Khanna, who developed the treatments, described the approval as exciting saying immunotherapy had great potential to target the spread of secondary cancer.

"When you are treating patients with chemo or radiotherapy, immunotherapy will become part of the normal treatment that is the ultimate goal," Khanna said. "One of the major advantages of immunotherapy is it is not as nasty or has side effects that the chemotherapy or radiotherapy has." Endi